Stock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report

Stock Track

May 21, 2025

CureVac B.V. (CVAC) shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.

According to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share (EPS) of -$0.21 for the quarter, indicating expected losses for the company. This negative outlook may be contributing to the downward pressure on the stock price as investors adjust their positions ahead of the official announcement.

The significant drop in CureVac's stock price suggests that market participants might be concerned about the company's financial performance or future prospects. As a biopharmaceutical company focused on developing a new class of transformative medicines, CureVac's earnings report will likely be closely scrutinized for insights into its ongoing research and development efforts, cash burn rate, and progress in its product pipeline. Investors will be keen to hear any updates on the company's mRNA technology platform and its potential applications in vaccines and therapeutics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1104693285"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104693285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104693285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104693285","market":"sg","top_or_hot":-1,"title":"Stock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report","media":"Stock Track","content":"<p>CureVac B.V. (CVAC) shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.</p>\n\n<p>According to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share (EPS) of -$0.21 for the quarter, indicating expected losses for the company. This negative outlook may be contributing to the downward pressure on the stock price as investors adjust their positions ahead of the official announcement.</p>\n\n<p>The significant drop in CureVac's stock price suggests that market participants might be concerned about the company's financial performance or future prospects. As a biopharmaceutical company focused on developing a new class of transformative medicines, CureVac's earnings report will likely be closely scrutinized for insights into its ongoing research and development efforts, cash burn rate, and progress in its product pipeline. Investors will be keen to hear any updates on the company's mRNA technology platform and its potential applications in vaccines and therapeutics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CureVac Stock Plummets 5.14% Ahead of Expected Q1 Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-21 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CureVac B.V. (CVAC) shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.</p>\n\n<p>According to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share (EPS) of -$0.21 for the quarter, indicating expected losses for the company. This negative outlook may be contributing to the downward pressure on the stock price as investors adjust their positions ahead of the official announcement.</p>\n\n<p>The significant drop in CureVac's stock price suggests that market participants might be concerned about the company's financial performance or future prospects. As a biopharmaceutical company focused on developing a new class of transformative medicines, CureVac's earnings report will likely be closely scrutinized for insights into its ongoing research and development efforts, cash burn rate, and progress in its product pipeline. Investors will be keen to hear any updates on the company's mRNA technology platform and its potential applications in vaccines and therapeutics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVAC","symbol_name":"CureVac B.V.","start_time":0,"source_url":"","article_id":"1104693285","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104693285","pubTimestamp":1747842035,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CureVac B.V.  shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.According to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share  of -$0.21 for the quarter, indicating ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVAC":"CureVac B.V."},"translate_title":"股票追踪CureVac股价在第一季度收益报告预期之前暴跌5.14%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":1},"content_text":"CureVac B.V. (CVAC) shares plunged 5.14% in Wednesday's trading session, as investors appear to be bracing for the company's upcoming first-quarter earnings report. The steep decline comes amid a broader context of anticipated financial results from various companies in the biotech and pharmaceutical sectors.\nAccording to a recently released earnings calendar, CureVac is scheduled to report its Q1 2025 results soon. Analysts are estimating an earnings per share (EPS) of -$0.21 for the quarter, indicating expected losses for the company. This negative outlook may be contributing to the downward pressure on the stock price as investors adjust their positions ahead of the official announcement.\nThe significant drop in CureVac's stock price suggests that market participants might be concerned about the company's financial performance or future prospects. As a biopharmaceutical company focused on developing a new class of transformative medicines, CureVac's earnings report will likely be closely scrutinized for insights into its ongoing research and development efforts, cash burn rate, and progress in its product pipeline. Investors will be keen to hear any updates on the company's mRNA technology platform and its potential applications in vaccines and therapeutics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}